Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myelodysplastic Syndromes
•
Hematology
How do you treat an MDS patient who presents with significant cytopenias who is not a candidate for lenalidomide or luspatercept? How do you initiate an HMA when they are severely neutropenic?
Related Questions
How do you manage a patient with low risk MDS who achieves transfusion independence with luspatercept but continues to have fatigue?
What is your approach for choosing between Imetelstat and Luspatercept in managing MDS related anemia?
How do you approach management for CCUS with severe cytopenias?
How do you approach severe anemia and thrombocytopenia in an elderly patient whose bone marrow biopsy shows hypercellular marrow with mild dysplasia in erythroid and megakaryocytic lineage but normal cytogenetics and a negative NGS panel?
How would you manage a stage IE Burkitt lymphoma with stable disease after three cycle of DA-R-EPOCH?
Can the presence of elevated ring sideroblasts (20%) on a bone marrow biopsy without dysplastic changes or suspicious molecular mutations still be indicative of an underlying MDS in a patient with unexplained anemia?
How would you counsel patients with personal or family histories of autoimmune disease on immune checkpoint inhibitor therapy for Hodgkin lymphoma?
What are your top takeaways in Hematologic Malignancies from ASH 2024?
How do you approach frontline treatment for an elderly patient with adult T-cell leukemia-lymphoma (ATL)?
How would you treat a tDLBCL originally treated with R-CHOP who relapses with DLBCL 15 years after the original diagnosis?
